Insider Trading Activity Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Director Sold 10,000 shares of Stock

Insider Trading Activity For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Stephen A Sherwin , Director of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) reportedly Sold 10,000 shares of the company’s stock at an average price of 98.44 for a total transaction amount of $984,400.00 SEC Form

Insider Trading History For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

  • On 6/21/2013 Dimitri E Grigoriadis, Insider, sold 46,837 with an average share price of $12.51 per share and the total transaction amounting to $585,930.87.
  • On 6/27/2013 Haig P Bozigian, Insider, sold 8,000 with an average share price of $13.00 per share and the total transaction amounting to $104,000.00.
  • On 6/28/2013 Christopher Flint Obrien, Insider, sold 11,357 with an average share price of $13.33 per share and the total transaction amounting to $151,388.81.
  • On 7/12/2013 Christopher Flint Obrien, Insider, sold 5,000 with an average share price of $14.50 per share and the total transaction amounting to $72,500.00.
  • On 8/5/2013 Timothy Coughlin, CFO, sold 10,965 with an average share price of $14.99 per share and the total transaction amounting to $164,365.35.
  • On 8/5/2013 Haig Bozigian, Insider, sold 11,001 with an average share price of $15.00 per share and the total transaction amounting to $165,015.00.
  • On 8/6/2013 W Thomas Mitchell, Director, sold 1,531 with an average share price of $14.70 per share and the total transaction amounting to $22,505.70.
  • Analyst Ratings History For Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

    • On 1/27/2017 CIBC Upgraded rating Market Perform ➝ Outperform
    • On 2/10/2017 ICAP Reiterated Rating Outperform with a price target of $55.00
    • On 2/16/2017 HC Wainwright Boost Price Target of rating Positive with a price target of $80.00 ➝ $100.00
    • On 3/7/2017 Cantor Fitzgerald Reiterated Rating Overweight with a price target of $80.00
    • On 11/2/2017 Citigroup Reiterated Rating Buy with a price target of $79.00
    • On 11/2/2017 BMO Capital Markets Boost Price Target of rating Positive ➝ Outperform with a price target of $83.00 ➝ $109.00
    • On 1/5/2018 Jefferies Financial Group Boost Price Target of rating Buy with a price target of $105.00

    Recent Trading Activity for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
    Shares of Neurocrine Biosciences, Inc. closed the previous trading session at with 294751 shares trading hands.

    An ad to help with our costs